The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors

被引:88
作者
McDonald, JM
See, SJ
Tremont, IW
Colman, H
Gilbert, MR
Groves, M
Burger, PC
Louis, DN
Giannini, C
Fuller, G
Passe, S
Blair, H
Jenkins, RB
Yang, H
Ledoux, A
Aaron, J
Tipnis, U
Zhang, W
Hess, K
Aldape, K
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA
[3] Johns Hopkins Univ, Sch Med, Dept Pathol, Div Neuropathol, Baltimore, MD USA
[4] Massachusetts Gen Hosp, Mol Neurooncol Lab, Boston, MA 02114 USA
[5] Massachusetts Gen Hosp, Mol Pathol Unit, Dept Pathol, Ctr Canc, Boston, MA 02114 USA
[6] Massachusetts Gen Hosp, Neurosurg Serv, Boston, MA 02114 USA
[7] Harvard Univ, Sch Med, Boston, MA 02115 USA
[8] Mayo Clin & Mayo Fdn, Dept Pathol, Rochester, MN 55905 USA
[9] Mayo Clin & Mayo Fdn, Div Lab Genet, Rochester, MN 55905 USA
[10] Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
关键词
oligodendroglioma; monomorphic pattern; nonrandom allelic loss; 1p/19q status; survival;
D O I
10.1002/cncr.21338
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. it has been reported previously that the combined loss of chromosomal arms 1p and 19q is a significant predictor of outcome for patients with anaplastic oligodendroglial (A0) tumors and that such chromosomal loss correlates with classic histology in A0. The authors sought to determine whether histology was an equivalent or superior predictor of outcome compared with 1p/19q status in 131 patients with A0 tumors. METHODS. The status of 1p and 19q was determined using real-time, quantitative polymerase chain reaction analysis and/or fluorescence in situ hybridization. Clinical features (response to adjuvant therapy and tumor location) and molecular genetic abnormalities (9p and 10q deletions, overexpression of p53 and epidermal growth factor receptor) were determined on available specimens. Histologic assessments for classic oligodendroglial features were performed by five neuropathologists. RESULTS. Classic histology was associated closely with 1p/19q loss, as reported previously. Patients who had tumors that were considered classic by at least four of the five neuropathologists showed significantly increased progression-free and overall survival compared with the patients who had less classic tumors. The authors also tested the correlation between 1p/19q status and outcome in subsets of patients stratified according to classic tumor features. The association of 1p/19q status with survival was related closely to the presence of classic histology. Loss of 1p/19q was predictive of improved outcome only among patients who had tumors with classic histologic features. CONCLUSIONS. The current results suggested that, in addition to 1p/19q status, histologic features contribute information to the prediction of outcome in patients with A0. Loss of 1p and 19q appeared to be a prognostic marker only in the subset of patients who had AO tumors with classic histologic features.
引用
收藏
页码:1468 / 1477
页数:10
相关论文
共 33 条
  • [1] EGFR overexpression and radiation response in glioblastoma multiforme
    Barker, FG
    Simmons, ML
    Chang, SM
    Prados, MD
    Larson, DA
    Sneed, PK
    Wara, WM
    Berger, MS
    Chen, PC
    Israel, MA
    Aldape, KD
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 51 (02): : 410 - 418
  • [2] Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas
    Bauman, GS
    Ino, Y
    Ueki, K
    Zlatescu, MC
    Fisher, BJ
    Macdonald, DR
    Stitt, L
    Louis, DN
    Cairncross, JG
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 48 (03): : 825 - 830
  • [3] Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization
    Bigner, SH
    Matthews, MR
    Rasheed, BKA
    Wiltshire, RN
    Friedman, HS
    Friedman, AH
    Stenzel, TT
    Dawes, DM
    McLendon, RE
    Bigner, DD
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (02) : 375 - 386
  • [4] Burger PC, 2002, BRAIN PATHOL, V12, P257
  • [5] Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections
    Burger, PC
    Minn, AY
    Smith, JS
    Borell, TJ
    Jedlicka, AE
    Huntley, BK
    Goldthwaite, PT
    Jenkins, RB
    Feuerstein, BG
    [J]. MODERN PATHOLOGY, 2001, 14 (09) : 842 - 853
  • [6] CHEMOTHERAPY FOR ANAPLASTIC OLIGODENDROGLIOMA
    CAIRNCROSS, G
    MACDONALD, D
    LUDWIN, S
    LEE, D
    CASCINO, T
    BUCKNER, J
    FULTON, D
    DROPCHO, E
    STEWART, D
    SCHOLD, C
    WAINMAN, N
    EISENHAUER, E
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (10) : 2013 - 2021
  • [7] Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas
    Cairncross, JG
    Ueki, K
    Zlatescu, MC
    Lisle, DK
    Finkelstein, DM
    Hammond, RR
    Silver, JS
    Stark, PC
    Macdonald, DR
    Ino, Y
    Ramsay, DA
    Louis, DN
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (19) : 1473 - 1479
  • [8] Concurrent hypermethylation of multiple genes is associated with grade of oligodendroglial tumors
    Dong, SM
    Pang, JCS
    Poon, WS
    Hu, J
    To, KF
    Chang, AR
    Ng, HK
    [J]. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2001, 60 (08) : 808 - 816
  • [9] Ginzinger DG, 2000, CANCER RES, V60, P5405
  • [10] Tumour necrosis and microvascular proliferation are associated with 9p deletion and CDKN2A alterations in 1p/19q-deleted oligodendrogliomas
    Godraind, C
    Rousseau, E
    Ruchoux, MM
    Scaravilli, F
    Vikkula, M
    [J]. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2003, 29 (05) : 462 - 471